Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Xiufeng, Hu"'
Publikováno v:
Heliyon, Vol 10, Iss 2, Pp e24378- (2024)
Background: Epidermal growth factor receptor (EGFR) mutations have been identified as promising therapeutic targets for non-small cell lung cancer. Osimertinib, a third-generation EGFR-tyrosine kinase inhibitor-targeting drug, has good anti-tumor abi
Externí odkaz:
https://doaj.org/article/dd8ce5e9b18d4033955f7f457963af7d
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
IntroductionIn murine cancer models, B cells are unnecessary for efficacy of PD-1 inhibitor. However, we do not know whether this applies to clinical settings, especially in patients with non-small-cell lung carcinoma (NSCLC).Case presentationWe repo
Externí odkaz:
https://doaj.org/article/d05d57fe9a8f47cd870ccfef34e708c1
Autor:
Yuanlin Xu, Xihong Zhang, Xiufeng Hu, Wenping Zhou, Peipei Zhang, Jiuyang Zhang, Shujun Yang, Yanyan Liu
Publikováno v:
Molecular Medicine, Vol 24, Iss 1, Pp 1-15 (2018)
Abstract Background For the study, we determine the potential biomarkers and uncover the regulatory mechanisms of lncRNA MALAT1 / miR-145 / SOX9 axis on the abilities of cell growth and cell metastasis of colorectal cancer. Methods Previously publish
Externí odkaz:
https://doaj.org/article/f2f3c7579f414361b997832b9d53387c
Publikováno v:
In Precision Engineering July 2015 41:111-118
Autor:
Donald Kufe, Kunihiko Hinohara, Tsuyoshi Hata, Masaaki Miyo, Yozo Suzuki, Xiufeng Hu, Audrey Bouillez, Maroof Alam, Ashujit Tagde, Hasan Rajabi, Caining Jin, Masayuki Hiraki, Takahiro Maeda
This file contains the results of studies with DOX-treated (i) BT-549 cells expressing a tet-CshRNA or tet-MUC1shRNA (S1A-S1D), (ii) MDA-MB-231 cells expressing a tet-CshRNA (S1E), and (iii) SUM-159 cells expressing a tet-MUC1shRNA (S1F).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dfcf2266d3cc3a7896466056bafdaf7
https://doi.org/10.1158/0008-5472.22416453
https://doi.org/10.1158/0008-5472.22416453
Autor:
Donald Kufe, Kunihiko Hinohara, Tsuyoshi Hata, Masaaki Miyo, Yozo Suzuki, Xiufeng Hu, Audrey Bouillez, Maroof Alam, Ashujit Tagde, Hasan Rajabi, Caining Jin, Masayuki Hiraki, Takahiro Maeda
This file contains ChIP qPCR primer pairs for the GAPDH and PD-L1 promoters.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::636b81055eb01425ccc20fd339c2b72f
https://doi.org/10.1158/0008-5472.22416432.v1
https://doi.org/10.1158/0008-5472.22416432.v1
Autor:
Donald Kufe, Kunihiko Hinohara, Tsuyoshi Hata, Masaaki Miyo, Yozo Suzuki, Xiufeng Hu, Audrey Bouillez, Maroof Alam, Ashujit Tagde, Hasan Rajabi, Caining Jin, Masayuki Hiraki, Takahiro Maeda
The immune checkpoint ligand PD-L1 and the transmembrane mucin MUC1 are upregulated in triple-negative breast cancer (TNBC), where they contribute to its aggressive pathogenesis. Here, we report that genetic or pharmacological targeting of the oncoge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50ae3882107886a14b3124b893eebe53
https://doi.org/10.1158/0008-5472.c.6509553.v1
https://doi.org/10.1158/0008-5472.c.6509553.v1
Autor:
Audrey Bouillez, Dennis Adeegbe, Caining Jin, Xiufeng Hu, Ashujit Tagde, Maroof Alam, Hasan Rajabi, Kwok-Kin Wong, Donald Kufe
Publikováno v:
OncoImmunology, Vol 6, Iss 9 (2017)
The cancer immune microenvironment is of importance for the effectiveness of immunotherapy; however, its dysregulation is poorly understood. The MUC1-C oncoprotein is aberrantly overexpressed in non-small cell lung cancer (NSCLC) and has been linked
Externí odkaz:
https://doaj.org/article/747e8e558ac24651b44a629deea789a1
Publikováno v:
Applied Energy. 338:120929
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::225eb508fbe9b73f59e9535785460ffc
https://doi.org/10.1016/j.apenergy.2023.120929
https://doi.org/10.1016/j.apenergy.2023.120929
Autor:
Lijuan Chen, Jie Liu, Xiufeng Hu, Huijuan Wu, Yanqiu Zhao, Hongbo Wu, Dong Han, Wenjing Liu, Xiao Han, Xiaoqian Mu
Publikováno v:
Aging. 12:20308-20331
The tumor immune microenvironment (TIME) is an important determinant of cancer prognosis and treatment efficacy. To identify immune-related prognostic biomarkers of lung adenocarcinoma, we used the ESTIMATE algorithm to calculate the immune and strom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5607c4353e262eeb4a134210441eb97f
https://doi.org/10.18632/aging.103804
https://doi.org/10.18632/aging.103804